Clinical Trial Detail

NCT ID NCT04339062
Title Cemiplimab in AlloSCT/SOT Recipients With CSCC (CONTRAC)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

skin squamous cell carcinoma

Therapies

Cemiplimab

Cemiplimab + Everolimus + Prednisone

Cemiplimab + Prednisone + Sirolimus

Age Groups: adult senior

No variant requirements are available.